- Posts: 1993
- Thank you received: 106
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
The only reason why I take for the first few days Clomid with Nolva is that I find nolva causes my vision to go blurry (hence I take it at night).
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
),Deca is a progestin (as are all nandrolones), unfortunately; it happens to stimulate the progesterone receptor 20% as well as progesterone itself
)Trenbolone is also a noted progestin: it binds to the receptor of the female sex hormone progesterone (with about 60% of the actual strength progesterone)
Many bodybuilders recommend using anti-prolactin drugs Bromocriptine or Cabaser / Dostinex (both Cabaser and Dostinex contain active ingredient Cabergoline), or even RU-486 “The abortion pill”, which is a progesterone blocker. These drugs have side effects are expensive and not commonly carried by many sources. I have heard reports from bodybuilders that bromocriptine didn’t help them, but strong anti-aromatase inhibitors like letrozole did. Therefore, it is better to use an anti-estrogen to combat tren based gyno. The only anti-estrogen I wouldn’t recommend for combatting this gyno is Nolva (tamoxifen) because in (J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):461-7) they found progesterone receptor expression increased, while it decreased with other anti-aromatase inhibitors.
J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9.
Aromatase inhibitors: cellular and molecular effects.
Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM.
Breast Unit, Western General Hospital, Edinburgh, Scotland, UK. EMAIL ADDRESS REMOVED
Marked cellular and molecular changes may occur in breast cancers following treatment of postmenopausal breast cancer patients with aromatase inhibitors. Neoadjuvant protocols, in which treatment is given with the primary tumour still within the breast, are particularly illuminating. In Edinburgh, we have shown that 3 months treatment with either anastrozole, exemestane or letrozole produces pathological responses in the majority of oestrogen receptor (ER)-rich tumours (39/59) as manifested by reduced cellularity/increased fibrosis. Changes in histological grading may also take place, most notably a reduction in mitotic figures. This probably reflects an influence on proliferation as most tumours (82%) show a marked decrease in the proliferation marker, Ki67. These effects are generally more dramatic than seen with tamoxifen given in the same setting. Differences between aromatase inhibitors and tamoxifen are also apparent in changes in steroid hormone expression. Thus, immuno-staining for progesterone receptor (PgR) is reduced in almost all cases by aromatase inhibitors, becoming undetectable in many. This contrasts with effects of tamoxifen in which the most common change on PgR is to increase expression. Changes in proliferation occur rapidly following the onset of exposure to aromatase inhibitors. Thus, neoadjuvant studies with letrozole in which tumour was sampled before and after 14 days and 3 months treatment show that decreased expression of Ki67 occur at 14 days and, in many cases, the effect is greater at 14 days than 3 months. These early changes precede evidence of clinical response but do not predict for it. However, this study design has allowed RNA analysis of sequential biopsies taken during the neoadjuvant therapy. Based on clustering techniques, it has been possible to subdivide tumours into groups showing distinct patterns of molecular changes. These changes in tumour gene expression may allow definition of tumour cohorts with differing sensitivity to aromatase inhibitors and permit early recognition of response and resistance.
Please Log in or Create an account to join the conversation.
Soooo, the oestrogen-like quality of nolvadex might actually interact with the progesterone/prolactin that comes with using 19nors to produce that OTHER type of gyno that makes men produce milk.
In other words, the tren gyno that comes from stacking test with tren might occur without the test if one is using nolvadex because nolvadex is so similar to the oestrogen that test converts to.
Tamoxifen increases the number of Progesterone receptors therefore escalating a pre-existing progesterone-gyno problem?
Mr. Jack Rabbit said:No just the first few days I like to take a bit more SERM so I can't take 40mg nolva or I struggle seeing clear so I find it easier taking a higher dose of clomid with the nolva for a few days to kick my PCT in
So no matter how similar these two SERMs are, they have different sides?
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
DJ cant you do me a favour since both conan or doc dont post anymore. Cant you ask him about finasteride usage during pct?should it be used only on cycle or during pct or half way into pct? I put this topic up and no one gave a concrete answer to it so since you communicate with em maybe you could just ask.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.